Applied BioMath applies mechanistic modeling to drug R&D to help biotechnology and pharmaceutical companies answer complex, scientific questions and make critical decisions for the advancement of drug candidates. A team of mathematicians, biologists, clinical pharmacologists and pharmaceutical industry experts, they leverage biology, mathematics, proprietary technologies, HPC, and industry experience to perform massive scale simulations which enable groups to determine best-in-class properties of a clinical candidate, reduce attrition rates, and identify key differentiators from competitors.
Ligand’s OmniAb® therapeutic antibody platforms produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity - Naturally optimized human antibodies®. The single-license OmniAb offering is the industry’s only with three species and multiple genetic backgrounds - 3 species, 1 license™
GenScript is the world leader in biotechnology, founded in 2002 and grown together with the synthetic biology industry and is now the world's leading gene synthesis supplier. Headquartered in New Jersey and with subsidiaries in Europe, Japan, and China. GenScript ProBio provides integrated & innovative biologics CDMO platform to accelerate the process from target to market and drive innovation further to develop therapeutic antibody and cell therapy platforms. We provide Antibody Discovery, Development services including plasmid and viral vectors. Our mission is making human and nature healthier through biotechnology.
Aragen Bioscience, Inc. is focused on accelerating antibody and other large-molecule product development. Our integrated preclinical research offerings include: antibody discovery, antibody humanization, recombinant protein production and purification, stable cell line development as well as cell-based assays and in vivo models-of-disease. Our team has been chosen for their scientific experience and diversity. We pride ourselves in our ability to understand each client’s unique needs, both, from a scientific as well as business perspective. This enables us to be not only a high-quality service provider, but also a preferred R&D partner. We’re located in the San Francisco, Bay Area.
Synaffix BV has established a proprietary site-specific antibody conjugation platform (GlycoConnect™) that was originally purposed for antibody-drug conjugates but has been adapted to rapidly generate immune cell-engagers and other bispecifics from any antibody without requiring recombinant DNA technology. The underlying GlycoConnect™ platform has delivered multiple clinical-stage assets and is commercially validated through licensing deals that total over $420m.